Get the Stockscreener App
318.21
0.16%
-0.50
Pre-market:
318.19
-0.02
-0.01%
Penumbra Inc stock is traded at $318.21, with a volume of 387.29K.
It is down -0.16% in the last 24 hours and down -1.28% over the past month.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
See More
Previous Close:
$318.71
Open:
$318.25
24h Volume:
387.29K
Relative Volume:
0.78
Market Cap:
$12.52B
Revenue:
$1.45B
Net Income/Loss:
$171.05M
P/E Ratio:
73.22
EPS:
4.3459
Net Cash Flow:
$212.73M
1W Performance:
-0.58%
1M Performance:
-1.28%
6M Performance:
+2.93%
1Y Performance:
+24.06%
1-Day Range:
$317.31
$319.83
1-Week Range:
$317.31
$322.09
52-Week Range:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
318.21 | 12.52B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-25 | Initiated | Wells Fargo | Underweight |
| Oct-08-25 | Upgrade | Needham | Hold → Buy |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
CE Mark Granted to Penumbra's CAVT Platform - dicardiology.com
Penumbra (PEN) Achieves CE Mark for Thunderbolt Technology - GuruFocus
Penumbra expands CAVT for stroke into Europe with Thunderbolt CE mark - NeuroNews International
Penumbra earns CE mark for Thunderbolt thrombectomy system - MassDevice
Penumbra’s Thunderbolt Computer-Assisted Vacuum Thrombectomy Earns CE Mark - Medical Product Outsourcing
Penumbra Inc Expands Cavt For Stroke To Europe With CE Mark For Thunderbolt - TradingView
Penumbra secures CE Mark for stroke treatment device in Europe - Investing.com
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT - PR Newswire
Boston Scientific Eyes Neurovascular Growth With Penumbra Thunderbolt Clearance - Yahoo Finance UK
Penumbra CAVT Platform Receives FDA Clearance - dicardiology.com
FDA clears Penumbra’s Thunderbolt thrombectomy platform for stroke - Yahoo Finance
FDA OKs Penumbra’s Thunderbolt Computer-Assisted Vacuum Thrombectomy for Stroke - Medical Product Outsourcing
Penumbra, Inc. to Present at the Canaccord Genuity Growth Conference - GuruFocus
Penumbra wins FDA clearance for Thunderbolt computer-assisted vacuum thrombectomy for stroke - MassDevice
Penumbra (PEN) Receives FDA Clearance for Innovative Thrombectom - GuruFocus
Penumbra receives FDA clearance for stroke treatment device By Investing.com - Investing.com Australia
Penumbra receives FDA clearance for stroke treatment device - Investing.com
Computer-guided THUNDERBOLT device designed to speed stroke clot removal - Stock Titan
Penumbra, Inc. to Present at the 41st Annual J.P. Morgan Healthc - GuruFocus
(PEN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Investor Outlook: Penumbra, Inc. (PEN) Boasts 13.36% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Total operating expenses of Penumbra, Inc. – XETR:0P8 - TradingView
Tangible book value per share of Penumbra, Inc. – XETR:0P8 - TradingView
Non-controlling/minority interest of Penumbra, Inc. – XETR:0P8 - TradingView
Penumbra, Inc. Cash Flow – XETR:0P8 - TradingView
Penumbra, Inc. Balance Sheet – XETR:0P8 - TradingView
PEN Technical Analysis & Stock Price Forecast - Intellectia AI
Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report? - Yahoo Finance
Here’s What Supports Penumbra’s (PEN) Revenue Growth and Margin Expansion - Insider Monkey
Grewal Harpreet, Penumbra director, sells $32,822 in stock - Investing.com
JP Morgan Upgrades Penumbra (PEN) - MSN
Penumbra Class Action Reminder - TMX Newsfile
Penumbra, Inc. (PEN) Stock Analysis: A Look At Growth Potential With A 14% Upside - DirectorsTalk Interviews
Decagon Asset Management LLP's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra Shareholder Notice - TMX Newsfile
Penumbra Shareholder Alert - TMX Newsfile
(PEN) Risk Channels and Responsive Allocation - Stock Traders Daily
RTW INVESTMENTS, LP's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra Inc stock (US70975L1070): shares steady after recent pullback as valuation comes into focus - AD HOC NEWS
Penumbra, Inc. (PEN) Stock Analysis: A Healthcare Giant With A 10.55% Upside Potential - DirectorsTalk Interviews
Neurovascular Devices Market Size, Share Growth Report 2034 - Fortune Business Insights
Water Island Event-Driven Fund's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra stock hits 52-week high at $328.69 By Investing.com - Investing.com Australia
Penumbra stock hits 52-week high at $328.69 - Investing.com
Penumbra (PEN) CEO-linked trust donates 77,000 shares in charitable stock gift - Stock Titan
Fortress Investment Group LLC's Penumbra Inc(PEN) Holding History - GuruFocus
Peripheral Embolization Coils Market is experiencing boost - openPR.com
PEN Stock Price, Quote & Chart | PENUMBRA INC (NYSE:PEN) - ChartMill
(PEN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ServisFirst Gets Axed by Champlain — a Minor Position in a Major Drawdown - The Motley Fool
HBK INVESTMENTS L P's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):